سعر اكسفورج 10مجم/160مجم 14 قرص 2024

Amlodipine 10 mg / valsartan 160 mg oral film-coated tablets (Exforge, Novartis), pack of 14.

• Treatment of hypertension, to lower blood pressure, in patients not adequately controlled on monotherapy.Population: AdultsDailyMed (U.S. NLM)
• Initial therapy of hypertension in patients likely to need multiple drugs to achieve their blood pressure goals.Population: AdultsDailyMed (U.S. NLM)
• Treatment of essential hypertension in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.Population: AdultsEuropean Medicines Agency

• Adverse reactions in clinical trials (>=2%, more than placebo): peripheral edema, nasopharyngitis, upper respiratory tract infection and dizziness; the most common reasons for discontinuation were peripheral edema and vertigo.International label, same product · DailyMed (U.S. NLM)

• Known hypersensitivity to any component; do not coadminister aliskiren with Exforge in patients with diabetes.International label, same product · DailyMed (U.S. NLM)
• EU: hypersensitivity to the active substances, dihydropyridine derivatives or excipients; severe hepatic impairment, biliary cirrhosis or cholestasis; aliskiren in patients with diabetes or renal impairment (GFR <60 mL/min/1.73 m2); second and third trimesters of pregnancy.International label, same product · European Medicines Agency

• Boxed warning - fetal toxicity: drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus; discontinue as soon as possible when pregnancy is detected.International label, same product · DailyMed (U.S. NLM)
• Hypotension: correct volume or salt depletion before starting; start under close supervision and cautiously in heart failure, recent myocardial infarction, surgery or dialysis.International label, same product · DailyMed (U.S. NLM)
• Worsening angina and acute myocardial infarction can develop after starting or increasing amlodipine, particularly in severe obstructive coronary artery disease.International label, same product · DailyMed (U.S. NLM)

• Moderate and strong CYP3A inhibitorsIncrease amlodipine exposure; may require dose reduction; monitor for hypotension and edema.DailyMed (U.S. NLM)
• CYP3A inducers (e.g. rifampicin, St John's wort)Effect on amlodipine not quantified; monitor blood pressure closely.DailyMed (U.S. NLM)
• SildenafilMonitor for hypotension when coadministered with amlodipine.DailyMed (U.S. NLM)

• Exforge can cause fetal harm; renin-angiotensin system drugs in the second and third trimesters reduce fetal renal function and increase fetal and neonatal morbidity and death; discontinue as soon as possible when pregnancy is detected.International label, same product · DailyMed (U.S. NLM)
• Limited data; valsartan is present in rat milk and amlodipine reportedly in human milk; because of potential serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment.International label, same product · DailyMed (U.S. NLM)

English text not available for this section.